SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome

Journal of Clinical Investigation

Volumn 124, Issue 4, 2014, Pages 1512-1524

  Alachkar, Houda ^a,b   Santhanam, Ramasamy ^a,b   Maharry, Kati ^b,c   Metzeler, Klaus H ^b   Huang, Xiaomeng ^a,b   Kohlschmidt, Jessica ^b,c   Mendler, Jason H ^a,b   Benito, Juliana M ^d   Hickey, Christopher ^a,b   Neviani, Paolo ^b,e   Dorrance, Adrienne M ^a,b   Anghelina, Mirela ^a,b   Khalife, Jihane ^a,b   Tarighat, Somayeh S ^a,b   Volinia, Stefano ^e   Whitman, Susan P ^b,e   Paschka, Peter ^b   Hoellerbauer, Pia ^a,b   Wu, Yue Zhong ^a,b   Han, Lina ^d   Bolon, Brad N ^b   Blum, William ^a,b   Mrózek, Krzysztof ^b   Carroll, Andrew J ^f   Perrotti, Danilo ^b,e   Andreeff, Michael ^d   Caligiuri, Michael A ^a,b   Konopleva, Marina ^d   Garzon, Ramiro ^a,b   Bloomfield, Clara D ^a,b   Marcucci, Guido ^a,b,e   more..

^a Oncology and Bone Marrow Transplantation   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Department of Molecular Virology Immunology and Cancer Genetics   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BORTEZOMIB; CD135 ANTIGEN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOCITRATE DEHYDROGENASE 2; MICRORNA 29B; MICRORNA 9; MYC PROTEIN; NUCLEOPHOSMIN; OSTEONECTIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CELL RENEWAL; CELL SELECTION; COLONY FORMATION; COLONY FORMING UNIT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ERYTHROBLASTOSIS; FLOW CYTOMETRY; LEUKEMIA CELL; LEUKEMIA REMISSION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSACTIVATION; TRANSIENT TRANSFECTION;

ADOLESCENT; ADULT; ANIMALS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MIDDLE AGED; NF-KAPPA B; OSTEONECTIN; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84897555169     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70921     Document Type: Article

References (81)

1. Swaroop A, Hogan BL, Francke U. Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics. 1988;2(1):37-47.
2. Lane TF, Sage EH. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J. 1994;8(2):163-173. (Pubitemid 24067139)
3. Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol. 1999;31(12):1363-1366.
4. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem. 1998;273(45):29635-29640. (Pubitemid 28509972)
5. Phan E, Ahluwalia A, Tarnawski AS. Role of SPARC - matricellular protein in pathophysiology and tissue injury healing. Implications for gastritis and gastric ulcers. Med Sci Monit. 2007;13(2):RA25-RA30. (Pubitemid 46238669)
6. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A. 1992;89(4):1281-1285.
7. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell. 2003;14(10):3977-3988. (Pubitemid 37186302)
8. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008;27(4):691-705.
9. Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene. 1996;12(9):1895-1901. (Pubitemid 26154661)
10. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza- 2′deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer. 2008;98(11):1810-1819. (Pubitemid 351748842)
11. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer. 2007;121(3):567-575. (Pubitemid 46986490)
12. Sato N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22(32):5021-5030. (Pubitemid 37026400)
13. Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005;72(4):267-272. (Pubitemid 40342998)
14. Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998;58(23):5529-5536. (Pubitemid 28551141)
15. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol. 1997;108(2):210-214. (Pubitemid 27061034)
16. Kato Y, et al. High production of SPARC/osteonectin/BM-40 in mouse metastatic B16 melanoma cell lines. Pathol Oncol Res. 2000;6(1):24-26. (Pubitemid 30262775)
17. Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA. Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci. 1999;17(5-6):463-472. (Pubitemid 29421833)
18. Koukourakis MI, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 2003;63(17):5376-5380. (Pubitemid 37139854)
19. Witkiewicz AK, et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther. 2010;10(4):391-396.
20. Liang JF, et al. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res. 2010;29:71.
21. Fidler C, Strickson A, Boultwood J, Waincoat JS. Mutation analysis of the SPARC gene in the 5q-syndrome. Am J Hematol. 2000;64(4):324. (Pubitemid 30622247)
22. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21(9):1931-1936. (Pubitemid 47299966)
23. Pellagatti A, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007;104(27):11406-11411. (Pubitemid 47175153)
24. DiMartino JF, et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 2006;20(3):426-432. (Pubitemid 43291739)
25. Fenouille N, et al. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res. 2010;70(23):9659-9670.
26. Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348-2355.
27. Schwind S, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(25):5660-5669.
28. Becker H, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4):596-604.
29. Payton JE, et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest 2009;119(6):1714-1726.
30. Sturm RA, et al. Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Res. 2002;62(1):226-232. (Pubitemid 34074009)
31. Pavasant P, Yongchaitrakul T. Secreted protein acidic, rich in cysteine induces pulp cell migration via αvβ3 integrin and extracellular signal-regulated kinase. Oral Dis. 2008;14(4):335-340. (Pubitemid 351533585)
32. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase - essential roles in physiology and cancer biology. J Cell Sci. 2008;121(pt 19):3121-3132.
33. Barker TH, et al. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem. 2005;280(43):36483-36493. (Pubitemid 41633922)
34. Weaver MS, Workman G, Sage EH. The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem 2008;283(33):22826-22837.
35. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci. 1999;56(5-6):523-537.
36. He XC, et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet. 2007;39(2):189-198. (Pubitemid 46184349)
37. Siapati EK, et al. Proliferation and bone marrow engraftment of AML blasts is dependent on beta-catenin signalling. Br J Haematol. 2011;152(2):164-174.
38. Wang Y, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650-1653.
39. Shi Q, et al. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem. 2004;279(50):52200-52209. (Pubitemid 39656594)
40. Nie J, Sage EH. SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. J Biol Chem. 2009;284(2):1279-1290.
41. Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, Rosen GD. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of β-catenin. J Biol Chem. 2010;285(11):8196-8206.
42. Lee SL, et al. Functional role of mTORC2 versus integrin-linked kinase in mediating Ser473-Akt phosphorylation in PTEN-negative prostate and breast cancer cell lines. PLoS One. 2013;8(6):e67149.
43. Tabe Y, et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007;67(2):684-694. (Pubitemid 46192208)
44. Zhu XC, et al. microRNA-29a suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma. Int J Mol Med. 2012;30(6):1321-1326.
45. Liu S, et al. Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17(4):333-347.
46. Luna C, Li G, Qiu J, Epstein DL, Gonzalez P. Role of miR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress. Mol Vis. 2009;15:2488-2497.
47. Kapinas K, Kessler CB, Delany AM. miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling. J Cell Biochem. 2009;108(1):216-224.
48. Garzon R, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411-6418.
49. Bernot KM, et al. Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease. Blood. 2013;122(23):3778-3783.
50. Blum W, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119(25):6025-6031.
51. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem. 1995;43(8):791-800.
52. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999;30(3):339-344. (Pubitemid 29125155)
53. McClung HM, Golembieski WA, Schultz CR, Jankowski M, Schultz LR, Rempel SA. Deletion of the SPARC acidic domain or EGF-like module reduces SPARC-induced migration and signaling through p38 MAPK/HSP27 in glioma. Carcinogenesis. 2012;33(2):275-284.
54. Golembieski WA, et al. HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion. Glia. 2008;56(10):1061-1075.
55. Yunker CK, et al. SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int J Cancer. 2008;122(12):2735-2743. (Pubitemid 351631375)
56. Ledda MF, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med. 1997;3(2):171-176.
57. Yiu GK, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol. 2001;159(2):609-622. (Pubitemid 32751091)
58. Aoi W, et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut. 2012;62(6):882-889.
59. Siva K, Jaako P, Miharada K. SPARC is dispensable for murine hematopoiesis, despite its suspected pathophysiological role in 5q- myelodysplastic syndrome. Leukemia. 2012;26(11):2416-2419.
60. Tripodo C, et al. Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation while its deficiency favors myeloid cell expansion. Blood. 2012;120(17):3541-3554.
61. Guzman ML, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002;99(25):16220-16225. (Pubitemid 35462776)
62. Mishra A, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012;22(5):645-655.
63. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005;5(1):51-63. (Pubitemid 40052325)
64. Shi Q, et al. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene. 2007;26(28):4084-4094. (Pubitemid 46920166)
65. Mims A, et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia. 2013;27(4):871-878.
66. Huang X, et al. Targeted delivery of microRNA-29b by transferrin- conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 2013;19(9):2355-2367.
67. Hickey CJ, et al. Lenalidomide-mediated enhanced translation of C/ EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 2013;121(1):159-169.
68. Eiring AM, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140(5):652-665.
69. Dorrance AM, et al. The Rac GTPase effector p21 activated kinase is essential for hematopoietic stem/progenitor cell migration and engraftment. Blood. 2013;121(13):2474-2482.
70. Liu S, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008;111(4):2364-2373. (Pubitemid 351451445)
71. Marcucci G, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742-750.
72. Mrozek K, et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol. 2008;33(2):239-244.
73. Thiede C, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335. (Pubitemid 34627197)
74. Whitman SP, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111(3):1552-1559. (Pubitemid 351213445)
75. Whitman SP, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007;109(12):5164-5167. (Pubitemid 46890532)
76. Caligiuri MA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56(6):1418-1425. (Pubitemid 26080988)
77. Dohner K, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-3746. (Pubitemid 41739007)
78. Becker H, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(5):788-792.
79. Marcucci G, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008;26(31):5078-5087.
80. Metzeler KH, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011;29(10):1373-1381.
81. Metzeler KH, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118(26):6920-6929.